Your session is about to expire
← Back to Search
Proteasome Inhibitor
Participants With Multiple Myeloma (MM) for Multiple Myeloma
N/A
Recruiting
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group
Summary
The main aim of this study is to check side effects and results in adults with multiple myeloma after switching from a bortezomib/carfilzomib -based to an Ixazomib-based treatment.
Eligible Conditions
- Multiple Myeloma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Progression Free Survival (PFS) at 24 Months
Secondary study objectives
Duration of CR
Duration of Ixazomib Therapy (DOT)
HRQOL Based on EORTC QLQ-C30
+9 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Participants With Multiple Myeloma (MM)Experimental Treatment1 Intervention
Participants diagnosed with MM (newly diagnosed multiple myeloma \[NDMM\] and first relapse multiple myeloma \[FRMM\]) using International Myeloma Working Group (IMWG) criteria who received a bortezomib/carfilzomib-based triple-drug regimens for more than 2 cycles as initial therapy, achieved at least partial response (PR) as defined by IMWG criteria, and are ready to start receiving an ixazomib containing therapy prescribed by their treating physician will be observed prospectively for 24 months.
Find a Location
Who is running the clinical trial?
TakedaLead Sponsor
1,234 Previous Clinical Trials
4,147,832 Total Patients Enrolled
50 Trials studying Multiple Myeloma
15,303 Patients Enrolled for Multiple Myeloma
Study DirectorStudy DirectorTakeda
1,270 Previous Clinical Trials
503,780 Total Patients Enrolled
25 Trials studying Multiple Myeloma
4,600 Patients Enrolled for Multiple Myeloma
Share this study with friends
Copy Link
Messenger